Advertisement
Organisation › Details
Intellegens Ltd.
Intellegens enables its customers to apply advanced machine learning methods through its Alchemite™ software, accelerating innovation in materials, chemicals, manufacturing, and beyond. The company’s mission is to be the leading machine learning solution for real-world, sparse and noisy data problems in industrial R&D and manufacturing processes. Alchemite™ originated at the University of Cambridge and development is on-going at Intellegens, in close collaboration with a growing community of customer organisations. These represent sectors including alloys, additive manufacturing, aerospace, batteries, biotechnology, ceramics, chemical processes, composites, consumer products, cosmetics, drug discovery, energy, food and beverage, formulated products, paints, plastics, and printing technology. *
Start | 2017-01-30 established (s-off) | |
Predecessor | University of Cambridge | |
Industry | artificial intelligence (AI) / machine learning (ML) | |
Industry 2 | Alchemite™ technology (AI) | |
Person | Pellegrini, Benjamin (Ben) (Intellegens 201701– CEO + Co-Founder) | |
Person 2 | Conduit, Gareth (Intellegens 201801 Founder) | |
Region | Cambridge, Cambridgeshire | |
Country | United Kingdom (GB) | |
Street | 28 Chesterton Mill The Studio | |
City | CB4 3NP Cambridge, Cambridgeshire | |
Tel | +44-118-328-2759 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Intellegens Ltd.. (8/30/23). "Press Release: Intellegens and CPI Awarded £1.6m Innovate UK Grant to Advance Manufacture of Oligonucleotide Therapeutics with Machine Learning". Cambridge. | ||
Record changed: 2023-08-31 |
Advertisement
More documents for Intellegens Ltd.
- [1] Intellegens Ltd.. (8/30/23). "Press Release: Intellegens and CPI Awarded £1.6m Innovate UK Grant to Advance Manufacture of Oligonucleotide Therapeutics with Machine Learning". Cambridge....
- [2] Intellegens Ltd.. (3/9/23). "Press Release: Intellegens Celebrates Milestone Opening of New Cambridge Headquarters". Cambridge....
- [3] Intellegens Ltd.. (4/11/22). "Press Release: Predicting Pharmacokinetics with Optibrium and AstraZeneca"....
- [4] Intellegens Ltd.. (3/24/22). "Press Release: Intellegens Announces Expansion"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top